Opinion of the Transparency Council – combining drug programmes B.29 and B.46

At its meeting on 18 July 2022 the Transparency Council adopted Opinion No. 110/2022 on the legitimacy of combining multiple sclerosis treatment drug programmes, i.e. B.29 and B.46.